HUP0301657A2 - Gombasejtfal-szintézisben szerepet járszó proteinkódoló gén - Google Patents

Gombasejtfal-szintézisben szerepet járszó proteinkódoló gén

Info

Publication number
HUP0301657A2
HUP0301657A2 HU0301657A HUP0301657A HUP0301657A2 HU P0301657 A2 HUP0301657 A2 HU P0301657A2 HU 0301657 A HU0301657 A HU 0301657A HU P0301657 A HUP0301657 A HU P0301657A HU P0301657 A2 HUP0301657 A2 HU P0301657A2
Authority
HU
Hungary
Prior art keywords
cell wall
transport
fungal cell
wall synthesis
synthesis gene
Prior art date
Application number
HU0301657A
Other languages
English (en)
Inventor
Katsura Hata
Junko Kai
Kazutaka Nakamoto
Fuminori Oba
Koji Sagane
Keigo Tanaka
Mamiko Tsuchya
Itaru Tsukada
Kappei Tsukahara
Norihiro Ueda
Naoaki Watanabe
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Publication of HUP0301657A2 publication Critical patent/HUP0301657A2/hu
Publication of HUP0301657A3 publication Critical patent/HUP0301657A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát DNS-ek képezik, amelyek gombák sejtfalánakszintézisében szerepet játszó proteineket kódolnak. Szintén atalálmány tárgyát képezik az ilyen DNS-ek által kódolt proteinek,valamint eljárások annak meghatározására, hogy egy adott vegyületbefolyásolja-e a GPI-kihorgonyzott proteinek sejtfalhoz történőszállításában szerepet játszó transzport folyamatot. Ezen túlmenően,olyan gombaellenes hatóanyagok is a találmány tárgyát képezik, amelyekbefolyásolják a GPI-kihorgonyzott proteinek sejtfalhoz történőszállításában szerepet játszó transzport folyamatot. A találmányszerinti megoldás alkalmas emlősök gombafertőzéseinek kezelésére. Ó
HU0301657A 2000-07-07 2001-07-06 Fungal cell wall synthesis gene HUP0301657A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000206968 2000-07-07
JP2000316027 2000-10-17
PCT/JP2001/005899 WO2002004626A1 (fr) 2000-07-07 2001-07-06 Gene de synthese de la paroi des cellules fongiques

Publications (2)

Publication Number Publication Date
HUP0301657A2 true HUP0301657A2 (hu) 2003-08-28
HUP0301657A3 HUP0301657A3 (en) 2010-01-28

Family

ID=26595616

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301657A HUP0301657A3 (en) 2000-07-07 2001-07-06 Fungal cell wall synthesis gene

Country Status (15)

Country Link
US (7) US7375204B2 (hu)
EP (1) EP1300464A4 (hu)
JP (3) JP4097194B2 (hu)
KR (1) KR100888946B1 (hu)
CN (1) CN1249227C (hu)
AU (2) AU2001269472B2 (hu)
BR (1) BR0112263A (hu)
CA (1) CA2415569A1 (hu)
HU (1) HUP0301657A3 (hu)
IL (1) IL153651A0 (hu)
MX (2) MXPA03000177A (hu)
NO (1) NO20030045L (hu)
NZ (2) NZ548265A (hu)
RU (1) RU2286387C2 (hu)
WO (1) WO2002004626A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004626A1 (fr) 2000-07-07 2002-01-17 Eisai Co., Ltd. Gene de synthese de la paroi des cellules fongiques
JP2005168301A (ja) * 2001-12-28 2005-06-30 Eisai Co Ltd 真菌細胞壁合成阻害活性を有する化合物をスクリーニングする方法
CA2721200A1 (en) * 2002-11-22 2004-06-10 Eisai R&D Management Co., Ltd. Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
WO2004048604A1 (ja) * 2002-11-22 2004-06-10 Eisai Co., Ltd. Gwt1遺伝子産物の酵素活性を阻害する化合物をスクリーニングする方法
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
CA2626767C (en) 2005-10-31 2012-01-17 Eisai R&D Management Co., Ltd. Heterocyclic substituted pyridine derivatives and antifungal agent containing same
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008035726A1 (fr) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
ES2325523B1 (es) * 2007-03-22 2010-06-24 Sumitomo Chemical Company, Limited Composicion agricola para controlar o prevenir enfermedades de las plantas provocadas por microbios patogeos de las plantas.
CN102702185A (zh) 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8522915B2 (en) * 2007-12-19 2013-09-03 Westerngeco L.L.C. Method and system for selecting parameters of a seismic source array
CN101910159B (zh) 2007-12-26 2013-06-19 卫材R&D管理有限公司 杂环取代吡啶衍生物的制备方法
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20110045482A1 (en) * 2008-02-11 2011-02-24 Research Foundation Of The City University Of New York Screening methods for identifying target antifungal genes and compounds by detecting cell surface glycoproteins
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US9956093B1 (en) * 2017-03-31 2018-05-01 Warren Harris Prosthetic limb cover
CN112986065B (zh) * 2021-02-08 2021-08-31 杭州同创医学检验实验室有限公司 一种用于血细胞分析仪的全血质控品及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013666A (en) * 1976-03-15 1977-03-22 G. D. Searle & Co. (8α,13Aβ)-8-CARBOCYCLIC/CARBOCYCLIC METHYL-5,8,13,13A-TETRAHYDRO-2,3,10,11-TETRAMETHOXY-6H-dibenzo[a,g]quinolizines and intermediates thereto
AU685057B2 (en) 1992-07-08 1998-01-15 Unilever Plc Process for immobilizing enzymes to the cell wall of a microbial cell by producing a fusion protein
AU4801393A (en) 1992-08-03 1994-03-03 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5641627A (en) * 1993-10-25 1997-06-24 Ribogene, Inc. Methods for screening for antimycotics
GB9324707D0 (en) 1993-12-02 1994-01-19 Olsen Odd Arne Promoter
ZA979496B (en) 1996-10-31 1999-04-23 Genentech Inc Assay using marked microbial host cell strains
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
DE19803208C2 (de) 1998-01-28 2003-04-30 Dietrich Haarer Substrat zum Verpacken von oder Anbringen an Produkten und Verfahren zur Qualitätsbestimmung
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
WO2000001387A1 (en) * 1998-07-01 2000-01-13 Celgro, A Division Of Celgene Corporation Fungal growth inhibitors
US6024719A (en) 1998-07-06 2000-02-15 Morris; Robert E Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS)
US20020072051A1 (en) * 2000-06-23 2002-06-13 Bulawa Christine Ellen Screen for identifying inhibitors of GPI anchoring
WO2002004626A1 (fr) * 2000-07-07 2002-01-17 Eisai Co., Ltd. Gene de synthese de la paroi des cellules fongiques
US6833447B1 (en) 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
CA2721200A1 (en) 2002-11-22 2004-06-10 Eisai R&D Management Co., Ltd. Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
WO2004048604A1 (ja) 2002-11-22 2004-06-10 Eisai Co., Ltd. Gwt1遺伝子産物の酵素活性を阻害する化合物をスクリーニングする方法
WO2005020888A2 (en) 2003-07-02 2005-03-10 Saint Louis University Compositions and methods of treating and diagnosing hepatoma
ZA200601124B (en) * 2003-08-20 2007-04-25 Univ Cape Town Position sensors
GB2413796B (en) 2004-03-25 2006-03-29 Global Genomics Ab Methods and means for nucleic acid sequencing

Also Published As

Publication number Publication date
RU2286387C2 (ru) 2006-10-27
MX2008013487A (es) 2009-03-06
US7541332B2 (en) 2009-06-02
JP2008206514A (ja) 2008-09-11
AU6947201A (en) 2002-01-21
WO2002004626A1 (fr) 2002-01-17
IL153651A0 (en) 2003-07-06
EP1300464A4 (en) 2006-02-01
US7999090B2 (en) 2011-08-16
US7928209B2 (en) 2011-04-19
CA2415569A1 (en) 2002-01-17
NZ548265A (en) 2008-06-30
US7910712B2 (en) 2011-03-22
MXPA03000177A (es) 2004-09-13
NO20030045L (no) 2003-03-06
HUP0301657A3 (en) 2010-01-28
CN1449443A (zh) 2003-10-15
KR100888946B1 (ko) 2009-03-17
US20060234349A1 (en) 2006-10-19
US20090098636A1 (en) 2009-04-16
NO20030045D0 (no) 2003-01-06
JP2006325589A (ja) 2006-12-07
AU2001269472C1 (en) 2002-01-21
US20090117586A1 (en) 2009-05-07
US7375204B2 (en) 2008-05-20
NZ541266A (en) 2006-11-30
US20080166765A1 (en) 2008-07-10
EP1300464A1 (en) 2003-04-09
CN1249227C (zh) 2006-04-05
AU2001269472B2 (en) 2006-05-11
JP4097194B2 (ja) 2008-06-11
US20080261272A1 (en) 2008-10-23
BR0112263A (pt) 2003-06-24
US20060234283A1 (en) 2006-10-19
KR20030027935A (ko) 2003-04-07
US7897387B2 (en) 2011-03-01
US20090325228A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
HUP0301657A2 (hu) Gombasejtfal-szintézisben szerepet járszó proteinkódoló gén
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
ATE354573T1 (de) ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
MY138593A (en) Shaped bodies containing metal-organic frameworks
ATE378337T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MXPA05013553A (es) Pirrolodihidroisoquinolinas como inhibidores de pde10.
DK1337629T3 (da) Dipeptidylpeptidaser
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
NO20054200D0 (no) Pyrazoler samt fremgangsmate for fremstilling derav
ATE403657T1 (de) Chemische verbindungen
BRPI0616630B8 (pt) compostos de pirazol substituídos
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
CY1109207T1 (el) Διαδικασια εχινοκανδινης
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
DE602006006544D1 (de) Neue pyrrolodihydroisochinoline als pde10-inhibitoren
DK1480491T3 (da) Tynd højttaler samt fremgangsmåde til fremstilling deraf
DE502006002531D1 (de) Verfahren zum herstellen von 5-fluor-1,3-dialkyl-1h-pyrazol-4-carbonsäurefluoriden
SE0300850D0 (sv) Chemical compounds
EA200870300A1 (ru) Способ водоотталкивающей обработки продукта на основе гипса, полученного из композиции на основе алебастра
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
SE0300957D0 (sv) Chemical compounds
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
DE60320132D1 (de) Verfahren zur herstellung von diketenacetalen
DE602004032548D1 (de) Derivate von hydroxamsäure als metalloproteinaseinhibitoren

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: EISAI R&D MANAGEMENT CO., LTD., JP

Free format text: FORMER OWNER(S): EISAI CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees